Last updated: March 5, 2026
What is NDC 00832-0273?
NDC 00832-0273 refers to Aflibercept Injection (brand name: Eylea), indicated primarily for treating neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). Approved by the FDA, its primary indication targets retinal vascular diseases.
Market Size and Growth Drivers
Current Market Scope
- Estimated global sales for aflibercept were approximately $4.2 billion in 2022, with the U.S. accounting for around 65% of the sales.
- The U.S. market alone exhibited sales of roughly $2.73 billion in 2022 (IQVIA).
Growth Drivers
- Rising prevalence of AMD, DME, RVO, and myopic choroidal neovascularization.
- Aging populations in North America, Europe, and Asia-Pacific.
- Advances in ophthalmic imaging and diagnostics increase diagnosis rates.
- Competitive landscape favors branded biologics, with limited biosimilar penetration as of 2023.
Key Market Players
| Company |
Product |
Market Share (2022) |
Notes |
| Regeneron / Bayer |
Eylea |
65% |
Dominates U.S. market |
| Roche / Novartis |
Lucentis |
20% |
Competes primarily in Europe and Asia |
| Other biosimilars |
- |
10-15% |
Entry threats rising |
Geographic Breakdown
| Region |
Estimated Market Share |
Key Insights |
| United States |
65% |
Largest, mature market |
| Europe |
20% |
Significant growth, slower saturation |
| Asia-Pacific |
10-15% |
Rapid growth, emerging markets |
Price Dynamics and Economic Factors
Historical Pricing
- Current list price (2023): Approximately $2,000–$2,200 per injection, with variations based on payer contracts and discounts.
- Average net price (after rebates and discounts): Estimated at $1,200–$1,500 per dose.
Pricing Trends
- Stabilized in the last five years due to cost-effectiveness and payer pressure.
- Biosimilar competition emerging could pressure prices downward after biosimilar approvals anticipated in the next 2-3 years.
Reimbursement and Payer Policies
- Medicare in the U.S. reimburses at approximately $2,000–$2,200 per injection.
- Commercial insurers negotiate discounts, reducing actual payer costs.
- Payer trends favor switch to biosimilars if price parity is achieved.
Price Projections (2024–2028)
Assumptions
- Continued growth in market volume at 5–7% annually due to increased diagnosis.
- Biosimilar approval anticipated by 2025, with a subsequent 15–20% reduction in average selling prices over the following 2 years.
- Moderate US price erosion expected due to payer discounting and competitive pressures.
Forecast Summary
| Year |
Estimated Global Sales |
Price per Dose (Net) |
Market Volume (Doses) |
Remarks |
| 2024 |
$4.7–$5.0 billion |
$1,350–$1,500 |
+6% annually |
Price pressure begins, biosimilar entry imminent |
| 2025 |
$5.2–$5.6 billion |
$1,200–$1,350 |
+7% annually |
Biosimilar approvals, increased competition |
| 2026 |
$5.7–$6.2 billion |
$1,150–$1,300 |
+6% annually |
Biosimilar market share gains (~20%) |
| 2027 |
$6.2–$6.8 billion |
$1,100–$1,250 |
+5% annually |
Price stabilization, continued volume growth |
| 2028 |
$6.7–$7.4 billion |
$1,050–$1,200 |
+4% annually |
Market maturity, biosimilar penetration mature |
Strategic Considerations
- Patent expiry for Eylea is anticipated around 2025 in the U.S., opening markets for biosimilar competition.
- Early biosimilar entrants are expected to target both pricing and contract negotiations.
- Contract negotiations and payer policies will heavily influence actual transaction prices.
- Market expansion into Asia-Pacific remains critical for long-term growth.
Key Takeaways
- The global market for aflibercept is projected to grow at 5–7% annually over the next five years.
- Prices are expected to decline gradually, influenced by biosimilar entries and payer negotiations.
- U.S. remains the dominant market, with a 65% share of global sales.
- Biosimilar approvals around 2025 could reduce prices by 15–20% within two years.
- Continued technological advances and expanding indications could sustain growth despite pricing pressures.
FAQs
1. When are biosimilars for aflibercept expected to enter the market?
Predicted approvals are around 2025; biosimilar market entry is expected within 6–12 months post-approval.
2. How much could biosimilar competition reduce prices?
Prices may decline by 15–20%, depending on the biosimilar market penetration and contractual agreements.
3. What regions besides the U.S. are critical for growth?
Europe and Asia-Pacific are vital, with Asia-Pacific experiencing rapid growth due to increasing healthcare infrastructure and prevalence of retinal diseases.
4. What factors could accelerate price declines?
Faster biosimilar approvals, widespread payer adoption of biosimilars, and regulatory policies promoting biosimilars.
5. How does reimbursement impact net pricing?
Payer discounts, rebates, and negotiated contracts significantly reduce the list price, impacting net revenue per dose.
References
[1] IQVIA. (2023). Global and U.S. pharmaceutical market data.
[2] FDA. (2022). Approved drugs for retinal vascular diseases.
[3] EvaluatePharma. (2023). 2023 World Preview: Outlook to 2028.
